Boron neutron capture therapy (BNCT) for liver metastasis: Therapeutic efficacy in an experimental model

Emiliano C.C. Pozzi; Jorge E. Cardoso; Lucas L. Colombo; Silvia Thorp; Andrea Monti Hughes; Ana J. Molinari; Marcela A. Garabalino; Elisa M. Heber; Marcelo Miller; Maria E. Itoiz; Romina F. Aromando; David W. Nigg; Jorge Quintana; Verónica A. Trivillin; Amanda E. Schwint

doi:10.1007/s00411-012-0419-8

Boron neutron capture therapy (BNCT) for liver metastasis: Therapeutic efficacy in an experimental model

Emiliano C.C. Pozzi
, Jorge E. Cardoso
, Lucas L. Colombo
, Silvia Thorp
, Andrea Monti Hughes
, Ana J. Molinari
, Marcela A. Garabalino
, Elisa M. Heber
, Marcelo Miller
, Maria E. Itoiz
, Romina F. Aromando
, David W. Nigg
, Jorge Quintana
, Verónica A. Trivillin
, Amanda E. Schwint

Nuclear Reactor Technology

Research output: Contribution to journal › Article › peer-review

40 Scopus citations

Abstract

Boron neutron capture therapy (BNCT) was proposed for untreatable colorectal liver metastases. The present study evaluates tumor control and potential radiotoxicity of BNCT in an experimental model of liver metastasis. BDIX rats were inoculated with syngeneic colon cancer cells DHD/K12/TRb. Tumor-bearing animals were divided into three groups: BPA-BNCT, boronophenylalanine (BPA) + neutron irradiation; Beam only, neutron irradiation; Sham, matched manipulation. The total absorbed dose administered with BPA-BNCT was 13 ± 3 Gy in tumor and 9 ± 2 Gy in healthy liver. Three weeks posttreatment, the tumor surface area post-treatment/pre-treatment ratio was 0.46 ± 0.20 for BPA-BNCT, 2.7 ± 1.8 for Beam only and 4.5 ± 3.1 for Sham. The pre-treatment tumor nodule mass of 48 ± 19 mgfell significantly to 19 ± 16 mg for BPA-BNCT, but rose significantly to 140 ± 106 mg for Beam only and to 346 ± 302 mg for Sham. For both end points, the differences between the BPA-BNCT group and each of the other groups were statistically significant (ANOVA). No clinical, macroscopic or histological normal liver radiotoxicity was observed. It is concluded that BPA- BNCT induced a significant remission of experimental colorectal tumor nodules in liver with no contributory liver toxicity.

Original language	English
Pages (from-to)	331-339
Number of pages	9
Journal	Radiation and Environmental Biophysics
Volume	51
Issue number	3
DOIs	https://doi.org/10.1007/s00411-012-0419-8
State	Published - Aug 2012

Keywords

BDIX rats
BNCT
Boron neutron capture therapy
DHD/K12/TRb cells
Experimental model
Liver metastasis

Access to Document

10.1007/s00411-012-0419-8

Cite this

Pozzi, E. C. C., Cardoso, J. E., Colombo, L. L., Thorp, S., Hughes, A. M., Molinari, A. J., Garabalino, M. A., Heber, E. M., Miller, M., Itoiz, M. E., Aromando, R. F., Nigg, D. W., Quintana, J., Trivillin, V. A., & Schwint, A. E. (2012). Boron neutron capture therapy (BNCT) for liver metastasis: Therapeutic efficacy in an experimental model. Radiation and Environmental Biophysics, 51(3), 331-339. https://doi.org/10.1007/s00411-012-0419-8

@article{ea8ea8630b9c4e0a852694302c22192c,

title = "Boron neutron capture therapy (BNCT) for liver metastasis: Therapeutic efficacy in an experimental model",

abstract = "Boron neutron capture therapy (BNCT) was proposed for untreatable colorectal liver metastases. The present study evaluates tumor control and potential radiotoxicity of BNCT in an experimental model of liver metastasis. BDIX rats were inoculated with syngeneic colon cancer cells DHD/K12/TRb. Tumor-bearing animals were divided into three groups: BPA-BNCT, boronophenylalanine (BPA) + neutron irradiation; Beam only, neutron irradiation; Sham, matched manipulation. The total absorbed dose administered with BPA-BNCT was 13 ± 3 Gy in tumor and 9 ± 2 Gy in healthy liver. Three weeks posttreatment, the tumor surface area post-treatment/pre-treatment ratio was 0.46 ± 0.20 for BPA-BNCT, 2.7 ± 1.8 for Beam only and 4.5 ± 3.1 for Sham. The pre-treatment tumor nodule mass of 48 ± 19 mgfell significantly to 19 ± 16 mg for BPA-BNCT, but rose significantly to 140 ± 106 mg for Beam only and to 346 ± 302 mg for Sham. For both end points, the differences between the BPA-BNCT group and each of the other groups were statistically significant (ANOVA). No clinical, macroscopic or histological normal liver radiotoxicity was observed. It is concluded that BPA- BNCT induced a significant remission of experimental colorectal tumor nodules in liver with no contributory liver toxicity.",

keywords = "BDIX rats, BNCT, Boron neutron capture therapy, DHD/K12/TRb cells, Experimental model, Liver metastasis",

author = "Pozzi, \{Emiliano C.C.\} and Cardoso, \{Jorge E.\} and Colombo, \{Lucas L.\} and Silvia Thorp and Hughes, \{Andrea Monti\} and Molinari, \{Ana J.\} and Garabalino, \{Marcela A.\} and Heber, \{Elisa M.\} and Marcelo Miller and Itoiz, \{Maria E.\} and Aromando, \{Romina F.\} and Nigg, \{David W.\} and Jorge Quintana and Trivillin, \{Ver{\'o}nica A.\} and Schwint, \{Amanda E.\}",

note = "Funding Information: Acknowledgments This study was supported in part by in-kind contributions from the US Department of Energy through Idaho National Laboratory, a grant from the National Agency for the Promotion of Science and Technology of Argentina (ANPCyT) and a grant from the National Research Council of Argentina (CONICET). The study sponsors were not involved in the study. The authors are indebted to the expert Maintenance, Radioprotection and Operation teams of RA-3.",

year = "2012",

month = aug,

doi = "10.1007/s00411-012-0419-8",

language = "English",

volume = "51",

pages = "331--339",

journal = "Radiation and Environmental Biophysics",

issn = "0301-634X",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "3",

}

Pozzi, ECC, Cardoso, JE, Colombo, LL, Thorp, S, Hughes, AM, Molinari, AJ, Garabalino, MA, Heber, EM, Miller, M, Itoiz, ME, Aromando, RF, Nigg, DW, Quintana, J, Trivillin, VA & Schwint, AE 2012, 'Boron neutron capture therapy (BNCT) for liver metastasis: Therapeutic efficacy in an experimental model', Radiation and Environmental Biophysics, vol. 51, no. 3, pp. 331-339. https://doi.org/10.1007/s00411-012-0419-8

TY - JOUR

T1 - Boron neutron capture therapy (BNCT) for liver metastasis

T2 - Therapeutic efficacy in an experimental model

AU - Pozzi, Emiliano C.C.

AU - Cardoso, Jorge E.

AU - Colombo, Lucas L.

AU - Thorp, Silvia

AU - Hughes, Andrea Monti

AU - Molinari, Ana J.

AU - Garabalino, Marcela A.

AU - Heber, Elisa M.

AU - Miller, Marcelo

AU - Itoiz, Maria E.

AU - Aromando, Romina F.

AU - Nigg, David W.

AU - Quintana, Jorge

AU - Trivillin, Verónica A.

AU - Schwint, Amanda E.

N1 - Funding Information: Acknowledgments This study was supported in part by in-kind contributions from the US Department of Energy through Idaho National Laboratory, a grant from the National Agency for the Promotion of Science and Technology of Argentina (ANPCyT) and a grant from the National Research Council of Argentina (CONICET). The study sponsors were not involved in the study. The authors are indebted to the expert Maintenance, Radioprotection and Operation teams of RA-3.

PY - 2012/8

Y1 - 2012/8

N2 - Boron neutron capture therapy (BNCT) was proposed for untreatable colorectal liver metastases. The present study evaluates tumor control and potential radiotoxicity of BNCT in an experimental model of liver metastasis. BDIX rats were inoculated with syngeneic colon cancer cells DHD/K12/TRb. Tumor-bearing animals were divided into three groups: BPA-BNCT, boronophenylalanine (BPA) + neutron irradiation; Beam only, neutron irradiation; Sham, matched manipulation. The total absorbed dose administered with BPA-BNCT was 13 ± 3 Gy in tumor and 9 ± 2 Gy in healthy liver. Three weeks posttreatment, the tumor surface area post-treatment/pre-treatment ratio was 0.46 ± 0.20 for BPA-BNCT, 2.7 ± 1.8 for Beam only and 4.5 ± 3.1 for Sham. The pre-treatment tumor nodule mass of 48 ± 19 mgfell significantly to 19 ± 16 mg for BPA-BNCT, but rose significantly to 140 ± 106 mg for Beam only and to 346 ± 302 mg for Sham. For both end points, the differences between the BPA-BNCT group and each of the other groups were statistically significant (ANOVA). No clinical, macroscopic or histological normal liver radiotoxicity was observed. It is concluded that BPA- BNCT induced a significant remission of experimental colorectal tumor nodules in liver with no contributory liver toxicity.

AB - Boron neutron capture therapy (BNCT) was proposed for untreatable colorectal liver metastases. The present study evaluates tumor control and potential radiotoxicity of BNCT in an experimental model of liver metastasis. BDIX rats were inoculated with syngeneic colon cancer cells DHD/K12/TRb. Tumor-bearing animals were divided into three groups: BPA-BNCT, boronophenylalanine (BPA) + neutron irradiation; Beam only, neutron irradiation; Sham, matched manipulation. The total absorbed dose administered with BPA-BNCT was 13 ± 3 Gy in tumor and 9 ± 2 Gy in healthy liver. Three weeks posttreatment, the tumor surface area post-treatment/pre-treatment ratio was 0.46 ± 0.20 for BPA-BNCT, 2.7 ± 1.8 for Beam only and 4.5 ± 3.1 for Sham. The pre-treatment tumor nodule mass of 48 ± 19 mgfell significantly to 19 ± 16 mg for BPA-BNCT, but rose significantly to 140 ± 106 mg for Beam only and to 346 ± 302 mg for Sham. For both end points, the differences between the BPA-BNCT group and each of the other groups were statistically significant (ANOVA). No clinical, macroscopic or histological normal liver radiotoxicity was observed. It is concluded that BPA- BNCT induced a significant remission of experimental colorectal tumor nodules in liver with no contributory liver toxicity.

KW - BDIX rats

KW - BNCT

KW - Boron neutron capture therapy

KW - DHD/K12/TRb cells

KW - Experimental model

KW - Liver metastasis

UR - https://www.scopus.com/pages/publications/84864465920

U2 - 10.1007/s00411-012-0419-8

DO - 10.1007/s00411-012-0419-8

M3 - Article

C2 - 22544068

AN - SCOPUS:84864465920

SN - 0301-634X

VL - 51

SP - 331

EP - 339

JO - Radiation and Environmental Biophysics

JF - Radiation and Environmental Biophysics

IS - 3

ER -

Boron neutron capture therapy (BNCT) for liver metastasis: Therapeutic efficacy in an experimental model

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this